Literature DB >> 16534183

Benign paroxysmal positional vertigo due to a simultaneous involvement of both horizontal and posterior semicircular canals.

Takao Imai1, Noriaki Takeda, Mahito Ito, Koji Nakamae, Hideki Sakae, Hiromu Fujioka, Takashi Matsunaga, Takeshi Kubo.   

Abstract

From April 2001 to November 2003, we investigated 8 patients with benign paroxysmal positional vertigo (BPPV) that was suspected to simultaneously affect both the horizontal and posterior semicircular canals (HSCC and PSCC). These cases showed typical vertical-torsional nystagmus induced by the Dix-Hallpike maneuver, followed by a horizontal nystagmus. They also showed a direction-changing geotropic or apogeotropic positional nystagmus triggered by lateral head rotations in the supine position. Using the three-dimensional analysis of the positional nystagmus, the rotation axis of the positional nystagmus had a component perpendicular to the plane of PSCC and another component perpendicular to the plane of HSCC. All these findings suggest that BPPV in these patients was a combination of posterior and horizontal canal BPPV. The observation of a vertical-torsional positional nystagmus should prompt the specialist to perform not only the canalith repositioning procedure, but also to execute lateral head turns in the supine position. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 16534183     DOI: 10.1159/000091892

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  2 in total

1.  Diagnosis of Single- or Multiple-Canal Benign Paroxysmal Positional Vertigo according to the Type of Nystagmus.

Authors:  Dimitris G Balatsouras; George Koukoutsis; Panayotis Ganelis; George S Korres; Antonis Kaberos
Journal:  Int J Otolaryngol       Date:  2011-07-14

2.  Clinical Interpretation of Positional Nystagmus Provoked by both Dix-Hallpike and Supine Head-Roll Tests.

Authors:  Evren Hizal; Sabuhi Jafarov; Seyra H Erbek; Levent N Ozluoglu
Journal:  J Int Adv Otol       Date:  2022-07       Impact factor: 1.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.